title: Efficient derivation of human cardiac precursors and cardiomyocytes from pluripotent human embryonic stem cells with small molecule induction.
abstract: To date, the lack of a suitable human cardiac cell source has been the major setback in regenerating the human myocardium, either by cell-based transplantation or by cardiac tissue engineering. Cardiomyocytes become terminally-differentiated soon after birth and lose their ability to proliferate. There is no evidence that stem/progenitor cells derived from other sources, such as the bone marrow or the cord blood, are able to give rise to the contractile heart muscle cells following transplantation into the heart. The need to regenerate or repair the damaged heart muscle has not been met by adult stem cell therapy, either endogenous or via cell delivery. The genetically stable human embryonic stem cells (hESCs) have unlimited expansion ability and unrestricted plasticity, proffering a pluripotent reservoir for in vitro derivation of large supplies of human somatic cells that are restricted to the lineage in need of repair and regeneration. Due to the prevalence of cardiovascular disease worldwide and acute shortage of donor organs, there is intense interest in developing hESC-based therapies as an alternative approach. However, how to channel the wide differentiation potential of pluripotent hESCs efficiently and predictably to a desired phenotype has been a major challenge for both developmental study and clinical translation. Conventional approaches rely on multi-lineage inclination of pluripotent cells through spontaneous germ layer differentiation, resulting in inefficient and uncontrollable lineage-commitment that is often followed by phenotypic heterogeneity and instability, hence, a high risk of tumorigenicity (see a schematic in Fig. 1A). In addition, undefined foreign/animal biological supplements and/or feeders that have typically been used for the isolation, expansion, and differentiation of hESCs may make direct use of such cell-specialized grafts in patients problematic. To overcome these obstacles, we have resolved the elements of a defined culture system necessary and sufficient for sustaining the epiblast pluripotence of hESCs, serving as a platform for de novo derivation of clinically-suitable hESCs and effectively directing such hESCs uniformly towards clinically-relevant lineages by small molecules (see a schematic in Fig. 1B). After screening a variety of small molecules and growth factors, we found that such defined conditions rendered nicotinamide (NAM) sufficient to induce the specification of cardiomesoderm direct from pluripotent hESCs that further progressed to cardioblasts that generated human beating cardiomyocytes with high efficiency (Fig. 2). We defined conditions for induction of cardioblasts direct from pluripotent hESCs without an intervening multi-lineage embryoid body stage, enabling well-controlled efficient derivation of a large supply of human cardiac cells across the spectrum of developmental stages for cell-based therapeutics.
authors.affiliation: San Diego Regenerative Medicine Institute, USA. parsons@SDRMI.org
authors.forename: Xuejun H
authors.initials: XH
authors.lastname: Parsons
authors.forename: Yang D
authors.initials: YD
authors.lastname: Teng
authors.forename: James F
authors.initials: JF
authors.lastname: Parsons
authors.forename: Evan Y
authors.initials: EY
authors.lastname: Snyder
authors.forename: David B
authors.initials: DB
authors.lastname: Smotrich
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Moore
mesh_terms: D003470:Culture Media; D003584:Cytological Techniques / Q000379:methods*; D053595:Embryonic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D032383:Myocytes, Cardiac / Q000166:cytology* / Q000187:drug effects; D009536:Niacinamide / Q000494:pharmacology*; D039904:Pluripotent Stem Cells / Q000166:cytology* / Q000187:drug effects
chemical_list: D003470:Culture Media; D009536:Niacinamide
references.citation: Nat Med. 2006 Nov;12(11):1259-68
references.pmid: 17057709
references.citation: Science. 1998 Nov 6;282(5391):1145-7
references.pmid: 9804556
references.citation: Nat Biotechnol. 2002 Sep;20(9):933-6
references.pmid: 12161760
references.citation: Cytotherapy. 2009;11(7):815-24
references.pmid: 19903095
references.citation: Nat Cell Biol. 2011 Mar;13(3):215-22
references.pmid: 21278734
references.citation: Transplant Rev (Orlando). 2009 Jan;23(1):53-68
references.pmid: 18657407
references.citation: Nature. 2008 May 15;453(7193):322-9
references.pmid: 18480813
references.citation: J Am Coll Cardiol. 2007 Nov 6;50(19):1884-93
references.pmid: 17980256
references.citation: Nature. 2011 Mar 3;471(7336):63-7
references.pmid: 21368825
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16707-12
references.pmid: 18922775
references.citation: Nature. 2008 Jan 10;451(7175):141-6
references.pmid: 18157115
references.citation: J Tissue Eng Regen Med. 2007 Sep-Oct;1(5):327-42
references.pmid: 18038427
references.citation: Pharmacol Ther. 2005 Aug;107(2):252-68
references.pmid: 15925411
references.citation: Nat Biotechnol. 2001 Oct;19(10):971-4
references.pmid: 11581665
references.citation: Cell. 2010 Aug 6;142(3):375-86
references.pmid: 20691899
references.citation: Nat Methods. 2005 Mar;2(3):185-90
references.pmid: 15782187
references.citation: Nat Protoc. 2007;2(8):1963-72
references.pmid: 17703208
references.citation: Nat Biotechnol. 2007 Sep;25(9):1015-24
references.pmid: 17721512
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5856-61
references.pmid: 18391196
references.citation: Nature. 2010 Sep 16;467(7313):285-90
references.pmid: 20644535
references.citation: Recent Pat Regen Med. 2011;1(2):142-163
references.pmid: 23355961
references.citation: Stem Cells. 2010 Apr;28(4):704-12
references.pmid: 20155819
references.citation: Nat Biotechnol. 2004 Oct;22(10):1282-9
references.pmid: 15448703